{"title":"Clinical evaluation of a new hypolipidemic drug, CIBA 13,437-Su","authors":"G Hartmann, G. Forster","doi":"10.1016/S0368-1319(69)80011-6","DOIUrl":null,"url":null,"abstract":"<div><p>The first clinical trials with a new aryloxy-type of hypolipidemic compound, the tetralin-derivative CIBA 13,437-Su, are reported. Various hyperlipidemic syndromes were treated in a total of 88 patients for periods up to 22 months.</p><p>With daily doses of 4–10 mg/kg, <em>i.e.</em> 300-600 mg per day, serum triglycerides and cholesterol were markedly lowered. The most pronounced effect was observed in hyperlipidemias of Types III, IV, and V of the Fredrickson-Lees classification. The pre-<em>β</em>-fraction appeared to be more readily lowered than the <em>β</em>-fraction, although the rather resistant hypercholesterolemia of Type II responded in all cases, yet to a lesser degree, and these patients received the higher doses. Slight transient increases in serum transaminases were observed in 7 out of 88 patients. The compound was very well tolerated subjectively. The results demonstrate that 13,437-Su is a very potent hypolipidemic agent.</p></div>","PeriodicalId":78351,"journal":{"name":"Journal of atherosclerosis research","volume":"10 2","pages":"Pages 235-246"},"PeriodicalIF":0.0000,"publicationDate":"1969-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0368-1319(69)80011-6","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of atherosclerosis research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0368131969800116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16
Abstract
The first clinical trials with a new aryloxy-type of hypolipidemic compound, the tetralin-derivative CIBA 13,437-Su, are reported. Various hyperlipidemic syndromes were treated in a total of 88 patients for periods up to 22 months.
With daily doses of 4–10 mg/kg, i.e. 300-600 mg per day, serum triglycerides and cholesterol were markedly lowered. The most pronounced effect was observed in hyperlipidemias of Types III, IV, and V of the Fredrickson-Lees classification. The pre-β-fraction appeared to be more readily lowered than the β-fraction, although the rather resistant hypercholesterolemia of Type II responded in all cases, yet to a lesser degree, and these patients received the higher doses. Slight transient increases in serum transaminases were observed in 7 out of 88 patients. The compound was very well tolerated subjectively. The results demonstrate that 13,437-Su is a very potent hypolipidemic agent.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
